rss
Ann Rheum Dis 73:e57 doi:10.1136/annrheumdis-2014-205973
  • Electronic pages
  • Correspondence response

Response to D.M. Marcus's comment on the TRIFRA study (comparison of Tripterygium wilfordii Hook F vs methotrexate in the treatment of active rheumatoid arthritis)

  1. Xuan Zhang1
  1. 1Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
  2. 2Formerly National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland, USA
  1. Correspondence to Dr Xuan Zhang, Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China; zxpumch2003{at}sina.com and Dr Peter E Lipsky, Formerly National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, 9000 Rockville Pike, Bethesda, MD 20892, USA; peterlipsky{at}comcast.net
  • Received 27 May 2014
  • Accepted 31 May 2014

We appreciate the comments of Dr Marcus1 concerning our article on the treatment of patients with rheumatoid arthritis with an extract of Tripterygium wilfordii Hook F (TwHF).2 While we agree that patient safety is of paramount concern, we would like to clarify a number of issues.

First, our study did not examine the efficacy of ‘the herb’ TwHF, but rather a pharmaceutical extract of specific parts of the plant. Various extracts of TwHF have been used in traditional Chinese medicine for hundreds of years for various symptoms. Because the plant contains hundreds of components, many of which have biological activity, standardisation has been difficult.3 However, over the past 30 years, intensive work by Chinese and …